(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2007, or

( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

---------------------------------------------------------------
Commission file number 0-17272

---------------------------------------------------------------
TECHNE CORPORATION
(Exact name of registrant as specified in its charter)

MINNESOTA                                         41-1427402
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

614 MCKINLEY PLACE N.E.                             (612) 379-8854
MINNEAPOLIS, MN         55413               (Registrant's telephone number, including area code)
(Address of principal executive offices) (Zip Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes (X) No ( )

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Securities Exchange Act.

Large accelerated filer (X) Accelerated filer ( ) Non-accelerated filer ( )

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2). ( ) Yes (X) No

At February 4, 2008, 39,025,280 shares of the Company's Common Stock (par value $.01) were outstanding.

TECHNE CORPORATION
FORM 10-Q
DECEMBER 31, 2007

INDEX
PAGE NO.
PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (unaudited)

Condensed Consolidated Balance Sheets as of December 31, 2007 and June 30, 2007    3

Condensed Consolidated Statements of Earnings for the Quarter and Six Months Ended December 31, 2007 and 2006    4
PART I. FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

TECHNE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
(unaudited)

<table>
<thead>
<tr>
<th></th>
<th>12/31/07</th>
<th>6/30/07</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASSETS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$148,657</td>
<td>$135,485</td>
</tr>
<tr>
<td>Short-term available-for-sale investments</td>
<td>40,139</td>
<td>29,289</td>
</tr>
<tr>
<td>Trade accounts receivable, net</td>
<td>29,273</td>
<td>29,559</td>
</tr>
<tr>
<td>Other receivables</td>
<td>1,465</td>
<td>1,407</td>
</tr>
<tr>
<td>Inventories</td>
<td>9,409</td>
<td>8,757</td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td>7,986</td>
<td>7,446</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>988</td>
<td>895</td>
</tr>
<tr>
<td>Total current assets</td>
<td>237,917</td>
<td>212,838</td>
</tr>
<tr>
<td>Availability for sale investments</td>
<td>95,663</td>
<td>91,433</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>94,478</td>
<td>91,535</td>
</tr>
<tr>
<td>Goodwill, net</td>
<td>25,068</td>
<td>25,068</td>
</tr>
<tr>
<td>Intangible assets, net</td>
<td>4,529</td>
<td>5,099</td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td>4,665</td>
<td>4,362</td>
</tr>
<tr>
<td>Investments in unconsolidated entities</td>
<td>25,096</td>
<td>24,165</td>
</tr>
<tr>
<td>Other assets</td>
<td>797</td>
<td>344</td>
</tr>
<tr>
<td>$488,213</td>
<td>$454,844</td>
<td></td>
</tr>
</tbody>
</table>

LIABILITIES AND STOCKHOLDERS' EQUITY

<table>
<thead>
<tr>
<th></th>
<th>12/31/07</th>
<th>6/30/07</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade accounts payable</td>
<td>$ 5,427</td>
<td>$ 5,098</td>
</tr>
<tr>
<td>Salaries, wages and related accruals</td>
<td>5,094</td>
<td>6,013</td>
</tr>
</tbody>
</table>
Other accounts payable and accrued expenses 4,396 1,836
Income taxes payable 4,941 4,246
Total current liabilities 19,858 17,193

Common stock, par value $0.01 per share; authorized 100,000,000; issued and outstanding 39,208,553 and 39,455,677, respectively 392 395
Additional paid-in capital 114,641 109,993
Retained earnings 340,426 314,339
Accumulated other comprehensive income 12,896 12,924
Total stockholders' equity 468,355 437,651

$488,213 $454,844

See notes to condensed consolidated financial statements.

TECHNE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(in thousands, except per share data)
(unaudited)

QUARTER ENDED SIX MONTHS ENDED
------------------  ------------------
12/31/07 12/31/06 12/31/07 12/31/06
--------  --------  --------  --------
Net sales $ 62,142 $ 52,509 $120,129 $104,860
Cost of sales 12,751 10,714 24,855 21,951
--------  --------  --------  --------
Gross margin 49,391 41,795 95,274 82,909
--------  --------  --------  --------
Operating expenses:
Selling, general and administrative 10,645 8,830 18,735 15,897
Research and development 5,562 5,044 10,743 9,899
Amortization of intangible assets 282 404 570 807
--------  --------  --------  --------
Total operating expenses 16,489 14,278 30,048 26,603
--------  --------  --------  --------
Operating income 32,902 27,517 65,226 56,306
--------  --------  --------  --------
Other expense (income):
Interest expense -- $ 815 $ 815
Interest income (3,252) (1,956) (6,250) (3,632)
Other non-operating expense, net 573 428 1,142 913
--------  --------  --------  --------
Total other income (2,679) (713) (5,108) (1,636)
--------  --------  --------  --------
Earnings before income taxes 35,581 28,804 70,118 54,670
Income taxes 11,942 9,567 23,623 19,648
--------  --------  --------  --------
Net earnings $ 23,639 $ 18,237 $ 46,495 $ 35,022
--------  --------  --------  --------
Earnings per share:
Basic $ 0.60 $ 0.47 $ 1.18 $ 0.97
Diluted $ 0.60 $ 0.47 $ 1.18 $ 0.97

Weighted average common shares outstanding:
Basic 39,395 39,387 39,442 39,383
Diluted 39,497 39,511 39,542 39,483

See notes to condensed consolidated financial statements.
SIX MONTHS ENDED
12/31/07  12/30/06

CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings                                           $ 46,711  $ 38,294
Adjustments to reconcile net earnings to
net cash provided by operating activities:
Depreciation and amortization                           3,383     3,386
Deferred income taxes                                   (844)     (551)
Stock-based compensation expense                       1,586     1,229
Excess tax benefit from stock option exercises          (400)     (108)
Losses by equity method investees                      493       373
Other                                                   42        110
Change in operating assets and operating
liabilities:
Trade accounts and other receivables                   697     1,291
Inventories                                            (971)     (290)
Prepaid expenses                                        (93)       25
Other                                                   324      (640)
Salaries, wages and related accruals                    561       147
Income taxes payable                                  1,172    (3,774)
--------  --------
Net cash provided by operating activities          52,661    39,492
--------  --------

CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment                      (5,747)   (3,807)
Purchase of available-for-sale investments              (30,860)  (17,200)
Proceeds from sales of available-for-sale investments    11,475     3,119
Proceeds from maturities of available-for-sale
investments                                            6,240    (8,145)
Increase in other assets                               (498)       --
Increase in investments in unconsolidated entities       (1,423)   (7,200)
--------  --------
Net cash used in investing activities             (20,813)  (16,943)
--------  --------

CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock                                  2,585       530
Excess tax benefit from stock option exercises              400       108
Purchase of common stock for stock bonus plans            (1,494)   (1,222)
Repurchase and retirement of common stock               (19,607)       --
Payments on long-term debt                                (13,427)
--------  --------
Net cash used in financing activities                (18,116)  (14,011)
--------  --------

Effect of exchange rate changes on cash                 (560)     4,386
Net increase in cash and cash equivalents                13,172    12,924
Cash and cash equivalents at beginning of period       135,485  89,634
--------  --------
Cash and cash equivalents at end of period              $148,657 $102,558

See notes to condensed consolidated financial statements.

5

TECHNE CORPORATION & SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

A. BASIS OF PRESENTATION:
The unaudited condensed consolidated financial statements of Techne
Corporation and subsidiaries (the Company) have been prepared in accordance
with accounting principles generally accepted in the United States of America
and with instructions to Form 10-Q and Article 10 of Regulation S-X. The
accompanying unaudited condensed consolidated financial statements reflect
all adjustments which are, in the opinion of management, necessary for a fair
presentation of the results for the interim periods presented. All such
adjustments are of a normal recurring nature.

A summary of significant accounting policies followed by the Company is detailed in the Company's Annual Report on Form 10-K for fiscal 2007. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2007 included in the Company's Annual Report to Shareholders for fiscal 2007.

Certain consolidated balance sheet captions appearing in this interim report are as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>12/31/07</th>
<th>6/30/07</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRADE ACCOUNTS RECEIVABLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade accounts receivable</td>
<td>29,415</td>
<td>29,700</td>
</tr>
<tr>
<td>Less allowance for doubtful accounts</td>
<td>142</td>
<td>141</td>
</tr>
<tr>
<td>NET TRADE ACCOUNTS RECEIVABLE</td>
<td>29,273</td>
<td>29,559</td>
</tr>
<tr>
<td>INVENTORIES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raw materials</td>
<td>3,612</td>
<td>3,821</td>
</tr>
<tr>
<td>Supplies</td>
<td>114</td>
<td>125</td>
</tr>
<tr>
<td>Finished goods</td>
<td>5,683</td>
<td>4,811</td>
</tr>
<tr>
<td>TOTAL INVENTORIES</td>
<td>9,409</td>
<td>8,757</td>
</tr>
<tr>
<td>PROPERTY AND EQUIPMENT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Land</td>
<td>4,214</td>
<td>4,214</td>
</tr>
<tr>
<td>Buildings and improvements</td>
<td>108,163</td>
<td>100,617</td>
</tr>
<tr>
<td>Building construction in progress</td>
<td>21,793</td>
<td>20,657</td>
</tr>
<tr>
<td>Laboratory equipment</td>
<td>4,665</td>
<td>4,407</td>
</tr>
<tr>
<td>Office equipment</td>
<td>4,665</td>
<td>4,407</td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>952</td>
<td>975</td>
</tr>
<tr>
<td>NET PROPERTY AND EQUIPMENT</td>
<td>94,478</td>
<td>91,535</td>
</tr>
<tr>
<td>INTANGIBLE ASSETS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Customer relationships</td>
<td>20,200</td>
<td>20,200</td>
</tr>
<tr>
<td>Technology</td>
<td>4,213</td>
<td>4,213</td>
</tr>
<tr>
<td>Trade names and trademarks</td>
<td>1,396</td>
<td>1,396</td>
</tr>
<tr>
<td>Supplier relationships</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>NET INTANGIBLE ASSETS</td>
<td>4,529</td>
<td>5,099</td>
</tr>
<tr>
<td>ACCUMULATED OTHER COMPREHENSIVE INCOME:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foreign currency translation adjustments</td>
<td>12,711</td>
<td>13,400</td>
</tr>
<tr>
<td>Unrealized gains (losses) on available-for-sale investments</td>
<td>185</td>
<td>(476)</td>
</tr>
<tr>
<td>TOTAL ACCUMULATED OTHER COMPREHENSIVE INCOME</td>
<td>12,896</td>
<td>12,924</td>
</tr>
</tbody>
</table>

B. EARNINGS PER SHARE:

Shares used in the earnings per share computations are as follows (in
Weighted average common shares outstanding-basic 39,395 39,387 39,442 39,383
Dilutive effect of stock options and warrants 102 124 100 100
Weighted average common shares outstanding-diluted 39,497 39,511 39,542 39,483

The dilutive effect of stock options and warrants in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 41,000 for both the quarter and six months ended December 31, 2007 and 7,000 and 37,000 for the quarter and six months ended December 31, 2006, respectively.

C. SEGMENT INFORMATION:

The Company has three reportable operating segments based on the nature of products and geographic location: biotechnology, R&D Systems Europe and hematology. The biotechnology segment consists of R&D Systems' Biotechnology Division, Fortron (through June 30, 2007 when it was merged into R&D Systems' Biotechnology Division), BiosPacific and R&D China, which develop, manufacture and sell biotechnology research and diagnostic products worldwide. R&D Systems Europe distributes Biotechnology Division products throughout Europe. The hematology segment develops and manufactures hematology controls and calibrators for sale worldwide.

The following table contains financial information relating to the Company’s operating segments in thousands:

<table>
<thead>
<tr>
<th>QUARTER ENDED</th>
<th>SIX MONTHS ENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/31/07</td>
<td>12/31/06</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>External sales</th>
<th>Biotechnology</th>
<th>R&amp;D Systems Europe</th>
<th>Hematology</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$39,143</td>
<td>$33,426</td>
<td>$78,024</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$34,476</td>
<td>$28,184</td>
</tr>
</tbody>
</table>

Total consolidated net sales $62,142 $52,509 $120,129 $104,860

Earnings before income taxes

<table>
<thead>
<tr>
<th>Biotechnology</th>
<th>$27,074</th>
<th>$22,978</th>
<th>$54,441</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D Systems Europe</td>
<td>$9,876</td>
<td>$6,592</td>
<td>$17,628</td>
</tr>
<tr>
<td>Hematology</td>
<td>$1,140</td>
<td>$1,145</td>
<td>$2,010</td>
</tr>
</tbody>
</table>
| Corporate and equity method investees (2,509) (2,485) (3,745) (3,498)

Total earnings before income taxes $35,581 $28,230 $70,334 $57,942

D. STOCK OPTIONS:

Option activity under the Company's stock option plans during the six months ended December 31, 2007 was as follows:

<table>
<thead>
<tr>
<th>WEIGHTED</th>
<th>WEIGHTED</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVG.</td>
<td>AVG.</td>
</tr>
<tr>
<td>SHARES</td>
<td>EXERCISE</td>
</tr>
<tr>
<td>(in 000's)</td>
<td>PRICE</td>
</tr>
<tr>
<td>----------</td>
<td>-------</td>
</tr>
<tr>
<td>Outstanding at June 30, 2007</td>
<td>423</td>
</tr>
<tr>
<td>Granted</td>
<td>38</td>
</tr>
</tbody>
</table>
Exercised (75) 35.07
Forfeited or expired (1) 36.50

Outstanding at December 31, 2007 385 $47.13 5.6 $7.3 million

Exercisable at December 31, 2007 335 $45.36 5.5 $7.0 million

The fair value of options granted under the Company's stock option plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:

<table>
<thead>
<tr>
<th>QUARTER ENDED</th>
<th>SIX MONTHS ENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/31/07 12/31/06</td>
<td>12/31/07 12/31/06</td>
</tr>
<tr>
<td>Dividend yield</td>
<td>-- -- -- --</td>
</tr>
<tr>
<td>Expected annualized volatility</td>
<td>46% 47% 24%-46% 31%-47%</td>
</tr>
<tr>
<td>Risk free interest rate</td>
<td>4.2% 4.7% 4.2%-4.6% 4.7%-5.1%</td>
</tr>
<tr>
<td>Expected life</td>
<td>8 years 8 years 7 years 7 years</td>
</tr>
<tr>
<td>Weighted average fair value of options granted</td>
<td>$37.12 $32.46 $35.75 $31.12</td>
</tr>
</tbody>
</table>

The Company has not paid cash dividends and does not have any plans to do so, therefore an expected dividend yield of zero was used to estimate fair value of options granted. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rate with a term consistent with the expected life of the options granted. Separate groups of employees that have similar historical exercise behavior with regard to option exercise timing and forfeiture rates are considered separately in determining option fair value.

The total intrinsic value of options exercised during the quarter and six months ended December 31, 2007 was $107,000 and $2.0 million, respectively. The total intrinsic value of options exercised during the quarter and six months ended December 31, 2006 was $199,000 and $254,000, respectively.

Stock option exercises are satisfied through the issuance of new shares. The total fair value of options vested during both the quarter and six months ended December 31, 2007 was $1.5 million. The total fair value of options vested during the quarter and six months ended December 31, 2006 was $1.3 million and $1.4 million, respectively.

Stock-based compensation cost of $1.4 million and $1.6 million was included in selling, general and administrative expense for the quarter and six months ended December 31, 2007, respectively. Stock-based compensation cost of $1.1 million and $1.2 million was included in selling, general and administrative expense for the quarter and six months ended December 31, 2006, respectively.

Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. As of December 31, 2007, there was $576,000 of total unrecognized compensation cost related to nonvested stock options that will be expensed over fiscal years 2008 through 2010.

E. COMPREHENSIVE INCOME:

Comprehensive income and the components of other comprehensive income were as follows (in thousands):

<table>
<thead>
<tr>
<th>QUARTER ENDED</th>
<th>SIX MONTHS ENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/31/07 12/31/06</td>
<td>12/31/07 12/31/06</td>
</tr>
<tr>
<td>Net earnings</td>
<td>$ 23,639 $ 18,663 $ 46,711 $ 38,294</td>
</tr>
<tr>
<td>Other comprehensive income, net of tax:</td>
<td></td>
</tr>
<tr>
<td>Foreign currency translation adjustments</td>
<td>(2,906) 3,645 (689) 4,451</td>
</tr>
</tbody>
</table>
Unrealized gain (loss) on available-for-sale investments  256 (55)  661  521

Comprehensive income  $ 20,989  $ 22,253  $ 46,683  $ 43,266

F. INCOME TAXES:

The Company adopted Financial Accounting Standards Board Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes, on July 1, 2007. The adoption of FIN 48 did not result in a cumulative effect adjustment to retained earnings upon adoption. FIN 48 did not materially impact the consolidated financial statements for the quarter and six months ended December 31, 2007. At December 31, 2007, unrecognized tax benefits were $154,000, including $55,000 of unrecognized tax benefits that, if recognized, would affect the effective tax rate. Accrued interest and penalties were not material at December 31, 2007.

The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease in the next twelve months. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. The Company files income tax returns in the U.S federal tax jurisdiction, the states of Minnesota and California, and several jurisdictions outside the U.S. U.S. tax returns for 2004 and subsequent years remain open to examination by the tax authorities. The Company's major non-U.S. tax jurisdictions are the United Kingdom, France and Germany, which have tax years open to exam for 2004 and subsequent years and China which has calendar year 2007 open to exam.

G. STOCK REPURCHASE:

In November 2007, the Board of Directors of the Company authorized the repurchase and retirement of $150 million of common stock. During the quarter ended December 31, 2007, the Company repurchased and retired approximately 321,000 shares of common stock for approximately $20.6 million. Included in other accounts payable at December 31, 2007 is $1.0 million for shares repurchased prior to December 31, 2007 which settled after that date.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations for the Quarter and Six Months Ended December 31, 2007 and the Quarter and Six Months Ended December 31, 2006

Overview

TECHNE Corporation and Subsidiaries (the Company) are engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted domestically through its wholly-owned subsidiary, Research and Diagnostic Systems, Inc (R&D Systems). The Company's wholly-owned U.K. subsidiary, R&D Systems Europe Ltd. (R&D Europe) distributes R&D Systems' biotechnology products throughout Europe. R&D Europe has a sales subsidiary, R&D Systems GmbH, in Germany and a sales office in France.

Through June 30, 2007, R&D Systems operated a subsidiary, Fortron Bio Science, Inc. (Fortron), a developer and manufacturer of monoclonal and polyclonal antibodies, antigens and other biological reagents. Subsequent to June 30, 2007, Fortron was merged into R&D Systems. A second R&D Systems subsidiary, BiosPacific, Inc. (BiosPacific), located in Emeryville, California, is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. In late fiscal 2007, R&D Systems established a subsidiary, R&D Systems China Co. Ltd. (R&D China), in Shanghai, China, to distribute biotechnology products throughout China. The

The Company has three reportable operating segments based on the nature of products and geographic location: biotechnology, R&D Systems Europe and hematology. The biotechnology segment consists of R&D Systems' Biotechnology Division, Fortron (through June 30, 2007), BiosPacific and R&D China, which develop, manufacture and sell biotechnology research and diagnostic products world-wide. R&D Systems Europe distributes Biotechnology Division products throughout Europe. The hematology segment develops and manufactures hematology controls and calibrators for sale world-wide.

10

Overall Results

Consolidated net earnings increased 26.7% and 22.0% for the quarter and six months ended December 31, 2007, respectively, compared to the quarter and six months ended December 31, 2006. The primary reason for the increase in consolidated net earnings was increased consolidated net sales. Consolidated net sales for the quarter and six months ended December 31, 2007, increased 18.4% and 14.6%, respectively, from the same periods in the prior year. The favorable impact on consolidated net sales of the change from the prior year in exchange rates used to convert R&D Europe results from British pound sterling to U.S. dollars was $1.0 million and $2.1 million for the quarter and six months ended December 31, 2007, respectively. The favorable impact on consolidated net earnings of the change from the prior year in exchange rates was $339,000 and $742,000 for the quarter and six months ended December 31, 2007, respectively. The Company generated cash of $52.7 million from operating activities in the first six months of fiscal 2008, paid cash of $19.6 million for the repurchase of common stock in the first six months of fiscal 2008 and had cash, cash equivalents and available-for-sale investments of $284 million at December 31, 2007 compared to $256 million at June 30, 2007.

Net Sales

Consolidated net sales for the quarter and six months ended December 31, 2007 were $62.1 million and $120.1 million, respectively, increases of $9.6 million (18.4%) and $15.3 million (14.6%) from the quarter and six months ended December 31, 2006. Biotechnology net sales increased $5.7 million (17.1%) and $8.7 million (12.5%), respectively, for the quarter and six months ended December 31, 2007. Approximately $1.6 million and $666,000 of the increase in biotechnology net sales for the quarter and six months ended December 31, 2007 was a result of increased volume and timing of shipments to diagnostic customers. The timing of shipments to diagnostic customer is not predictable and these sales increases are not necessarily indicative of future sales. Excluding sales to diagnostic customers, biotechnology net sales increased 12.9% and 12.3% for the quarter and six months ended December 31, 2007, respectively.

R&D Europe net sales increased $3.8 million (24.7%) and $6.3 million (22.3%) for the quarter and six months ended December 31, 2007. The effect of changes from the prior year in foreign currency exchange rates used to convert British pound sterling to U.S. dollars increased R&D Europe net sales approximately $1.0 million and $2.1 million for the quarter and six months ended December 31, 2007, respectively. In British pound sterling, R&D Europe net sales increased 18.5% and 14.8% for the quarter and six months ended December 31, 2007, respectively, mainly as a result of increased sales volume.

Hematology sales increase $147,000 (3.8%) and $301,000 (4.1%) for the quarter and six months ended December 31, 2007 as a result of increased sales volume.

The Company has target annual sales growth rates for each of its business segments. The target sales growth rates, which are based on historical sales growth, are 10%-12% for biotechnology, 7%-9% for R&D Europe (in constant currency) and 1%-2% for hematology. Based on the relative size of each segment, the consolidated target annual growth rate for fiscal 2008 is 8%-11% excluding the effect of changes in exchange rates. Due to the strong sales growth in the second quarter of fiscal 2008 and the Easter holiday falling in March 2008, the sales growth rate for the third quarter is expected to be below the second quarter growth rate.
Gross Margins

Gross margins, as a percentage of net sales, were as follows:

<table>
<thead>
<tr>
<th></th>
<th>QUARTER ENDED</th>
<th>SIX MONTHS ENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/31/07</td>
<td>12/31/06</td>
<td>12/31/07</td>
</tr>
<tr>
<td>Biotechnology</td>
<td>79.4%</td>
<td>80.8%</td>
</tr>
<tr>
<td>R&amp;D Europe</td>
<td>56.4%</td>
<td>52.0%</td>
</tr>
<tr>
<td>Hematology</td>
<td>42.7%</td>
<td>43.9%</td>
</tr>
<tr>
<td>Consolidated gross</td>
<td>79.5%</td>
<td>79.6%</td>
</tr>
<tr>
<td>margin</td>
<td>80.2%</td>
<td>52.1%</td>
</tr>
<tr>
<td></td>
<td>79.3%</td>
<td>42.1%</td>
</tr>
<tr>
<td></td>
<td>79.1%</td>
<td></td>
</tr>
</tbody>
</table>

Consolidated gross margins, as a percentage of net sales, decreased slightly from 79.6% for the quarter ended December 31, 2006 to 79.5% for the quarter ended December 31, 2007 and increased slightly from 79.1% for the six months ended December 31, 2006 to 79.3% for the six months ended December 31, 2007. The decrease for the quarter was mainly the result of increased sales to diagnostic customers, which reduced biotechnology gross margins from 80.8% for the quarter ended December 31, 2006 to 79.4% for the quarter ended December 31, 2007. This decrease was partially offset by increased gross margins by R&D Europe for the quarter ended December 31, 2007 as a result of favorable exchange rates. The increase in gross margins for the six months ended December 31, 2007 as compared to the same prior-year period was a result of increased gross margins by R&D Europe as a result of favorable exchange rates and changes in sales mix as a result of higher sales growth in biotechnology and R&D Europe as compared to the sales growth in the lower margin hematology business.

The Company values its manufactured protein and antibody inventory based on a two-year forecast. Quantities in excess of the two-year forecast are considered impaired and are not included in the inventory value. Sales of previously impaired protein and antibody inventory for the quarter and six months ended December 31, 2007 and 2006 were not material.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the quarter and six months ended December 31, 2007, increased $1.8 million (20.6%) and $2.8 million (17.9%), respectively, from the same periods of last year. Selling, general and administrative expenses are composed of the following (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>QUARTER ENDED</th>
<th>SIX MONTHS ENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/31/07</td>
<td>12/31/06</td>
<td>12/31/07</td>
</tr>
<tr>
<td>Biotechnology</td>
<td>$5,534</td>
<td>$4,664</td>
</tr>
<tr>
<td>R&amp;D Europe</td>
<td>2,599</td>
<td>2,405</td>
</tr>
<tr>
<td>Hematology</td>
<td>487</td>
<td>439</td>
</tr>
<tr>
<td>Corporate</td>
<td>2,025</td>
<td>1,322</td>
</tr>
<tr>
<td>Total selling,</td>
<td>$10,645</td>
<td>$8,830</td>
</tr>
<tr>
<td>general and administrative</td>
<td>$18,735</td>
<td>$15,897</td>
</tr>
<tr>
<td>expenses</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The increase from the comparable prior-year periods was the result of the following (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>QUARTER ENDED</th>
<th>SIX MONTHS ENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional profit</td>
<td>295</td>
<td>481</td>
</tr>
<tr>
<td>sharing expense</td>
<td></td>
<td></td>
</tr>
<tr>
<td>China selling,</td>
<td>144</td>
<td>244</td>
</tr>
<tr>
<td>general and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>administrative expense</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R&amp;D Europe:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in exchange</td>
<td>116</td>
<td>283</td>
</tr>
<tr>
<td>rates to convert</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British pounds to U.S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dollars</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Hematology:
  Additional profit sharing expense                        36           55

Corporate:
  Additional professional fees                            340          386
  Additional stock expense                                352          357

The increase in profit sharing expense for the quarter and six months ended December 31, 2007 was the result of the increased sales and earnings from the same prior-year periods. Operations in China were established in late fiscal 2007, resulting in increased expenses in fiscal 2008. The increase in professional fees and stock expense was due to additional legal fees and an increase in the number of stock options granted in the second quarter of fiscal 2008 compared to the second quarter of fiscal 2007 as a result of expanding the Board of Directors by one member. The remainder of the increase in selling, general and administrative expenses for the quarter and six months ended December 31, 2007, was mainly the result of annual wage and salary increases and the hiring of additional marketing and administrative personnel.

Research and Development Expenses

Research and development expenses are composed of the following (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>QUARTER ENDED</th>
<th>SIX MONTHS ENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotechnology</td>
<td>$ 5,368</td>
<td>$ 4,854</td>
</tr>
<tr>
<td>Hematology</td>
<td>194</td>
<td>190</td>
</tr>
<tr>
<td></td>
<td>$ 5,562</td>
<td>$ 5,044</td>
</tr>
</tbody>
</table>

Total research and development expenses $ 10,743 $ 9,899

Interest Expense

On October 31, 2006, the Company repaid its mortgage debt. Included in interest expense for the quarter ended December 31, 2006 was a prepayment penalty of $651,000 and $78,000 of unamortized loan origination fees.

Other Non-operating Expense and Income

Other non-operating expense and income consists mainly of foreign currency transaction gains and losses, rental income, building expenses related to rental property, and the Company's share of losses by equity method investees.

<table>
<thead>
<tr>
<th></th>
<th>QUARTER ENDED</th>
<th>SIX MONTHS ENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreign currency (gains) losses</td>
<td>$ (153)</td>
<td>$ (126)</td>
</tr>
<tr>
<td>Rental income</td>
<td>(111)</td>
<td>(241)</td>
</tr>
<tr>
<td>Real estate taxes, depreciation and utilities</td>
<td>600</td>
<td>549</td>
</tr>
<tr>
<td>Hemerus Medical, LLC losses</td>
<td>113</td>
<td>123</td>
</tr>
<tr>
<td>Nephromics, LLC losses</td>
<td>124</td>
<td>123</td>
</tr>
<tr>
<td>Total other non-operating expense</td>
<td>$ 573</td>
<td>$ 428</td>
</tr>
</tbody>
</table>

The Company currently holds an 18% equity interest in Hemerus Medical, LLC (Hemerus) and at December 31, 2007, the Company's net investment in Hemerus was $2.9 million. The Company accounts for its investment in Hemerus using the equity method of accounting because Hemerus is a limited liability company. The Company has financial exposure to the losses of Hemerus to the extent of its net investment in that entity. Hemerus' success is dependent, in part, upon its ability to raise financing and receiving Federal Drug
Administration (FDA) clearance to market its products. If such financing or FDA clearance is not received, the Company would potentially recognize an impairment loss to the extent of its remaining net investment.

In fiscal 2007, the Company invested $7.2 million for an 18% equity interest in Nephromics, LLC (Nephromics). The Company accounts for its investment in Nephromics using the equity method of accounting because Nephromics is a limited liability company. At December 31, 2007, the Company's net investment in Nephromics was $6.5 million. The Company has financial exposure to any losses of Nephromics to the extent of its net investment in that entity.

Income Taxes

Income taxes for both the quarter and six months ended December 31, 2007 were provided at rates of 33.6% of consolidated earnings before income taxes compared to 33.9% of consolidated earnings before income taxes for both the quarter and six months ended December 31, 2006. U.S. federal taxes have been reduced by the credit for research and development expenditures, the benefit for extraterritorial income through December 2006 and the manufacturer’s deduction available under the American Jobs Creation Act of 2004. Foreign income taxes have been provided at rates that approximate the tax rates in the countries in which R&D Europe and R&D China operate. Without significant business developments, the Company expects income tax rates for the remainder of fiscal 2008 to range from approximately 33.5% to 34.5%.

Liquidity and Capital Resources

At December 31, 2007, cash and cash equivalents and available-for-sale investments were $284 million compared to $256 million at June 30, 2007. The Company believes it can meet its future cash, working capital and capital addition requirements through currently available funds, cash generated from operations and maturities of available-for-sale investments. The Company has an unsecured line of credit of $750,000. The interest rate on the line of credit is at prime. There were no borrowings on the line in the prior or current fiscal year.

Cash Flows From Operating Activities

The Company generated cash of $52.7 million from operating activities in the first six months of fiscal 2008 compared to $39.5 million in the first six months of fiscal 2007. The increase from the prior year was primarily due to an increase in consolidated net earnings in the current year of $8.4 million and the change in consolidated income taxes payable during the six months ended December 31, 2007 compared to the same prior-year period. Income taxes payable increased during the six months ended December 31, 2007 mainly as a result of increased income taxes currently payable of $3.7 million and a reduction of $674,000 in deposits made from the same prior-year period.

Cash Flows From Investing Activities

Capital expenditures for fixed assets for the first six months of fiscal 2008 and 2007 were $5.7 million and $3.8 million, respectively. Included in capital expenditures for the first six months of fiscal 2008 and 2007 were $4.3 million and $2.4 million, respectively, for building renovation and construction. The remaining capital additions in the first six months of fiscal 2008 and 2007 were for laboratory and computer equipment. Capital expenditures in the remainder of fiscal 2008 are expected to be approximately $2.4 million and are expected to be financed through currently available funds and cash generated from operating activities.

During the six months ended December 31, 2007, the Company purchased $30.9 million and had sales or maturities of $17.7 million of available-for-sale investments. During the six months ended December 31, 2006, the Company purchased $17.2 million and had sales or maturities of $11.3 million of available-for-sale investment. The Company’s investment policy is to place excess cash in bonds and other investments with maturities of less than three years. The objective of this policy is to obtain the highest possible return with minimal risk, while keeping the funds accessible.
In December 2007, the Company invested $1.4 million for a 19% interest in ACTGen, Inc., a development stage biotechnology company located in Japan. In September 2006, the Company invested $7.2 million for an 18% equity interest in Nephromics, LLC. The investments were financed through cash and equivalents on hand.

Cash Flows From Financing Activities

Cash of $2.6 million and $530,000 was received during the six months ended December 31, 2007 and 2006, respectively, from the exercise of stock options. The Company also recognized excess tax benefits from stock option exercises of $400,000 and $108,000 for the six months ended December 31, 2007 and 2006, respectively.

During the first six months of fiscal 2008 and 2007, the Company purchased 23,641 shares and 22,400 shares of common stock, respectively, for its employee stock bonus plans at a cost of $1.5 millions and $1.2 million, respectively.

During the first six months of fiscal 2008, the Board of Directors authorized the Company, subject to market conditions and share price, to purchase an additional $150 million of its common stock. During the first six months of fiscal 2008, the Company purchased and retired approximately 321,000 shares of common stock at a market value of $20.6 million of which $19.6 was disbursed prior to December 31, 2007.

The Company has never paid cash dividends and has no plans to do so in fiscal 2008.

Critical Accounting Policies

The Company's significant accounting policies are discussed in the Company's Annual Report on Form 10-K for fiscal 2007. The application of certain of these policies require judgments and estimates that can affect the results of operations and financial position of the Company. Judgements and estimates are used for, but not limited to, accounting for the allowance for doubtful accounts, inventory valuation and allowances, impairment of goodwill, intangibles and other long-lived assets, accounting for investments and income taxes. There have been no significant changes in estimates in fiscal 2008 which would require disclosure. There have been no changes to the Company's policies in fiscal 2008.

Recent Accounting Pronouncements

In December 2007, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standard (SFAS) No. 141 (revised 2007), Business Combinations, which replaces SFAS No. 141. The statement retains the purchase method of accounting for acquisitions, but requires a number of changes, including changes in the way assets and liabilities are recognized in the purchase accounting. It also changes the recognition of assets acquired and liabilities assumed arising from contingencies, requires the capitalization of in-process research and development at fair value, and requires the expensing of acquisition-related costs as incurred. SFAS No. 141R must be applied prospectively to business combinations consummated by the Company beginning in fiscal 2010.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements, an Amendment of ARB No. 51 to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. Among other requirements, SFAS No. 160 clarifies that a noncontrolling interest in a subsidiary, which is sometimes referred to as minority interest, is to be reported as a separate component of equity in the consolidated financial statements. SFAS No. 160 also requires consolidated net income to include the amounts attributable to both the parent and the noncontrolling interest and to disclose those amounts on the face of the consolidated statement of income. SFAS No. 160 must be applied prospectively by the Company beginning in fiscal 2010, except for the presentation and disclosure requirements, which will be applied retrospectively for all periods presented.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. The Statement establishes a single authoritative definition of fair value, sets
out a framework for measuring fair value, and requires additional disclosures about fair value measurements. SFAS No. 157 applies only to fair value measurements that are already required or permitted by other accounting standards and is effective for the Company in fiscal 2009. The Company is currently evaluating the impact of adopting SFAS No. 157.

Forward Looking Information and Cautionary Statements

This filing contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements include those regarding the Company's expectations as to target sales growth rates, compensation expense resulting from stock option expensing, the effective tax rate, the sufficiency of currently available funds for meeting the Company's needs and capital expenditures. These statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, the retention of hematology OEM (private label) and proficiency survey business, the impact of currency exchange rate fluctuations, the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships, and the success of financing efforts by companies in which the Company has invested. For additional information concerning such factors, see the Company's Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

At December 31, 2007, the Company had an investment portfolio of fixed income securities, excluding those classified as cash and cash equivalents, of $136 million. These securities, like all fixed income instruments, are subject to interest rate risk and will decline in value if market interest rates increase.

The Company operates internationally, and thus is subject to potentially adverse movements in foreign currency rate changes. The Company is exposed to market risk from foreign exchange rate fluctuations of the euro, the British pound sterling and the Chinese yuan to the U.S. dollar as the financial position and operating results of the Company's U.K. subsidiary, European operations and Chinese subsidiary are translated into U.S. dollars for consolidation. At the current level of R&D Europe operating results, a 10% increase or decrease in the average exchange rate used to translate operating results into U.S. dollars would have an approximate $2.2 million effect on consolidated operating income annually.

The Company's exposure to foreign exchange rate fluctuations also arises from transferring funds from the U.K. and Chinese subsidiaries to the U.S. subsidiary and from transferring funds from the German subsidiary and French sales office to the U.K. subsidiary. At December 31, 2007 and 2006, the Company had $3.6 million and $4.6 million, respectively, of dollar denominated intercompany debt at its U.K. subsidiary and at December 31, 2007, the Company had $391,000 dollar denominated intercompany debt at its Chinese subsidiary. At December 31, 2007 and 2006, the U.K. subsidiary had $532,000 and $506,000, respectively, of dollar denominated intercompany debt from its European operations. These intercompany balances are revolving in nature and are not deemed to be long-term balances.

The Company's subsidiaries recognized net foreign currency gains and (losses) as follows (in thousands):

<table>
<thead>
<tr>
<th>QUARTER ENDED</th>
<th>SIX MONTHS ENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>In Native Currency</td>
<td></td>
</tr>
<tr>
<td>12/31/07 12/31/06 12/31/07 12/31/06</td>
<td></td>
</tr>
<tr>
<td>R&amp;D Europe (British pound)</td>
<td>81</td>
</tr>
<tr>
<td>R&amp;D China (Chinese yuan)</td>
<td>(90)</td>
</tr>
</tbody>
</table>
The Company does not enter into foreign exchange forward contracts to reduce its exposure to foreign currency rate changes on intercompany foreign currency denominated balance sheet positions.

### ITEM 4 - CONTROLS AND PROCEDURES

As of the end of the period covered by this report, the Company conducted an evaluation, under the supervision and with the participation of the principal executive officer and principal financial officer, of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")). Based on this evaluation, the principal executive officer and principal financial officer concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. There was no change in the Company's internal control over financial reporting during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

### PART II. OTHER INFORMATION

#### ITEM 1 - LEGAL PROCEEDINGS

None.

#### ITEM 1A. - RISK FACTORS

There have been no material changes from the risk factors previously disclosed in Part I, Item 1A, "Risk Factors," of the Company's Annual Report on Form 10-K for the year ended June 30, 2007.

#### ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table sets forth the repurchases of Company common stock for the quarter ended December 31, 2007:

<table>
<thead>
<tr>
<th>Total Number of Shares Purchased</th>
<th>Maximum Approximate Dollar Value of Shares as Part of Plans</th>
<th>As Part of Plans that May Yet be Purchased Under Plans or Programs</th>
<th>Maximum Approximate Dollar Value of Shares Purchased Per Share or Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/1/07-10/31/07</td>
<td>0</td>
<td>0</td>
<td>$ 6.8 million</td>
</tr>
<tr>
<td>11/1/07-11/30/07</td>
<td>246,184</td>
<td>$63.22</td>
<td>246,184</td>
</tr>
<tr>
<td>12/1/07-12/31/07</td>
<td>75,141</td>
<td>$67.41</td>
<td>75,141</td>
</tr>
</tbody>
</table>

In October 2002, the Company authorized the purchase and retirement of $20 million of its common stock of which $6.8 million remained at October 31, 2007. In November 2007, the Company authorized the repurchase and retirement of an additional $150 million of common stock. The stock repurchase authorization does not have an expiration date.

### ITEM 3 - DEFAULTS UPON SENIOR SECURITIES
ITEM 4 - SUBMISSION OF MATTERS TO VOTE OF SHAREHOLDERS

Information relating to the Company's Annual Meeting of Shareholders, held on October 25, 2007 is contained in the Company's Form 10-Q for the quarter ended September 30, 2007, which is incorporated herein by reference.

ITEM 5 - OTHER INFORMATION

None.

ITEM 6 - EXHIBITS

See exhibit index following.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TECHNE CORPORATION
(Company)

Date: February 5, 2008 /s/ Thomas E. Oland

---------------------------
President, Chief Executive Officer

February 5, 2008 /s/ Gregory J. Melsen

---------------------------
Chief Financial Officer

EXHIBIT INDEX
TO
FORM 10-Q

TECHNE CORPORATION

Exhibit # Description

10.1 Employment agreement, dated January 30, 2008 with Marcel Veronneau

31.1 Section 302 Certification

31.2 Section 302 Certification

32.1 Section 906 Certification

32.2 Section 906 Certification
EMPLOYMENT AGREEMENT

DATE: January 30, 2008

PARTIES:        Techne Corporation, a
               Minnesota corporation
               614 McKinley Place N.E.
               Minneapolis, Minnesota 55413

                           Marcel Veronneau
                           1896 Park Ridge Ct.
                           St. Paul, Minnesota 55119

AGREEMENTS:

ARTICLE 1.
TERM OF EMPLOYMENT: DUTIES AND SUPERVISION

1.1) Parties. The parties to this Agreement are Marcel Veronneau
("Employee") and Techne Corporation ("Company"). As used herein, Company
refers to Techne Corporation and its subsidiaries including Research and
Diagnostic Systems, Inc. ("R&D"), unless specifically provided otherwise.
All of the rights and obligations created by this Agreement may be performed
by or enforced by or against the Company or R&D or other appropriate
subsidiary.

1.2) Term of Employment. The Company hereby employs Employee as Vice
President, Hematology Operations of the Company for the term beginning
January 30, 2008 and continuing through June 30, 2010 unless employment
terminates earlier as provided in Article 5 hereof.

1.3) Duties and Supervision. During the term of this Agreement,
Employee agrees to devote his full time and best efforts to the business and
affairs of the Company, and to perform such services and duties
Employee may from time to time be assigned by the Company, and specifically
its President.

ARTICLE 2.
COMPENSATION

2.1) Salary. During the first fiscal year of the term of this
Agreement (July 1, 2007 through June 30, 2008), the Company shall pay to
Employee as base compensation for services to be rendered hereunder an annual
salary of $160,000, to be paid semi-monthly or in accordance with the usual
payroll practices of the Company. Each subsequent fiscal year during the
term of Employee's employment by the Company, under this Agreement,
Employee's salary shall be reviewed but not reduced by the President of
the Company.

2.2) Management Incentive Bonus Plan. During each fiscal year of the term of
Employee's employment, Employee shall be eligible to earn a bonus
equal to 40%, as herein defined, of his base compensation. The performance
standards for earning such bonus shall be established annually by the
President of the Company but the eligibility for a 40% bonus shall not be
amended during the term of this Agreement except with the consent of
Employee. At least one-half of such bonus shall be paid in the form
of stock options with an aggregate exercise price equal to such one-half of
the bonus amount. Such options are to be granted immediately after receipt
of audited financial statements for the previous fiscal year and the
Corresponding close of the previous fiscal year. The exercise price is to be
based on the market price of the Company's Common Stock on the date of grant.
The other one-half of any bonus earned may be taken, at the election of the
Employee, either in cash or in additional stock options with an exercise
price equal to 170% of such one-half of the bonus amount.

2.3) Other Employee Compensation and Benefits. In addition to the
compensation and benefits provided to Employee in Sections 2.1 and 2.2
hereof, Employee shall be entitled to participate in other employee
compensation and benefit plans from time to time established by the Company and made available generally to all employees. Employee shall participate in such compensation and benefit plans on an appropriate and comparable basis determined by the Board of Directors by reference to all other employees eligible for participation. With regard to all insured benefits to be provided to Employee, benefits shall be subject to due application by Employee, the Company has no obligation to pay insured benefits directly and such benefits are payable to Employee only by the insurers in accordance with their policies. Employee shall not be reimbursed for unused personal days or sick days.

ARTICLE 3.
PAYMENT OF CERTAIN EXPENSES

3.1) Business Expenses. In order to enable Employee to better perform the services required of him hereunder, the Company shall pay or reimburse Employee for business expenses in accordance with policies to be determined from time to time by the Board of Directors. Employee agrees to submit documentation of such expenses as may be reasonably required by Company.

ARTICLE 4.
INVENTIONS, PROPRIETARY INFORMATION AND COMPETITION

4.1) Prior Agreement. Neither the execution of this Agreement nor any provision in it shall be interpreted as rescinding or revoking the Employee Agreement With Respect To Inventions, Proprietary Information, and Unfair Competition previously entered into between the Company and Employee as of February 2, 1993 (the "Prior Agreement"). The Company and Employee hereby agree that the terms of such Prior Agreement shall apply to all businesses of the Company, including not only business conducted by the Company but also to business conducted through Techne or any subsidiary or venture of Techne now existing or hereafter created. The termination of this Employment Agreement shall not terminate Employee's obligations under the Prior Agreement.

ARTICLE 5.
TERMINATION

5.1) Events of Termination. Employee's employment shall terminate as follows:

(A) By mutual written agreement of the parties.

(B) Upon death of Employee;

(C) Employee may terminate his employment at any time upon written notice provided to the Board of Directors at least 90 days prior to the effective date of termination.

(D) The Company may terminate Employee's employment as follows:

(i) In the event of the merger, sale of the business, or change in control of the Company, provided that the salary and bonus continuation provisions of Article 6.1 of this Agreement are met.

(ii) By written notice to Employee, the Company may terminate Employee's employment immediately with cause. For purposes of this Agreement, "cause" shall mean material dishonesty or gross misconduct on the part of Employee in the performance of Employee's duties hereunder, serious breach of Company policies or failure on the part of Employee to perform material duties assigned to Employee by the Company's President or Board of Directors.

(iii) Upon the occurrence of physical or mental disability of Employee to such an extent that Employee is unable to carry on essential functions of Employee's position, with or without reasonable accommodation, and such inability continues for a period of three months. Nothing in this Section 5.1(D)(iii) shall limit the right of either party to
terminate this Agreement under one of the other sections of this Section 5.1.

5.2) Records and Files. In the event of termination of employment of Employee hereunder, possession of each corporate file and record shall be retained by the Company, and Employee or his heirs, assigns and legal representatives shall have no right whatsoever in any such material, information or property.

ARTICLE 6.
TERMINATION BENEFITS

6.1) Termination Benefits. In the event Employee's employment by the Company is terminated in connection with a merger, sale, or "change in control" of the Company or any subsidiary of the Company, Employee shall be paid at the time of such termination an amount equal to the lesser of (a) one month's base salary as provided by section 2.1 of this Agreement for each full year during which Employee has been employed by the Company, or (b) two times Employee's annualized compensation for the tax year preceding the year of termination (as evidenced by Employee's W-2 for such preceding year), or, if less, two times the compensation limit under Internal Revenue Code Section 401(a)(17); provided, however, that Employee shall be entitled to the payment set forth in this Section 6.1 only if he executes and does not rescind a release agreement in a form supplied by the Company, which will include, but not be limited to, a comprehensive release of claims against the Company and all related parties, in their official and individual capacities. For purposes of this Section 6.1, "change in control" means the acquisition in one or more transactions by a single party, or any number of parties acting in concert, of a majority of the outstanding shares of voting stock of the Company.

ARTICLE 7.
MODIFICATIONS

7.1) Modifications. Except as provided in Section 4.1 above, this Agreement supersedes all prior agreements and understandings between the parties relating to the employment of Employee by the Company and it may not be changed or terminated orally. No modification, termination, or attempted waiver of any of the provisions of this Agreement shall be valid unless in writing signed by the party against whom the same is sought to be enforced.

ARTICLE 8.
GOVERNING LAW AND SEVERABILITY

8.1) Governing Law. The validity, enforceability, construction and interpretation of this Agreement shall be governed by the laws of the State of Minnesota.

8.2) Severability. If any term of this Agreement is deemed unenforceable, void, voidable, or illegal, such unenforceable, void, voidable or illegal term shall be deemed severable from all other terms of this Agreement which shall continue in full force and effect and the Company and Employee expressly acknowledge that a court of competent jurisdiction may, at Company's request, modify and thereafter enforce any of the terms, conditions, and covenants contained in this Agreement.

ARTICLE 9.
BINDING EFFECT

9.1) Binding Effect. The breach by the Company of any other agreement or instrument between the Company and Employee shall not excuse or waive Employee's performance under, or compliance with, this Agreement. This Agreement shall be binding upon and inure to the benefit of the Company, its successors and assigns, and Employee, his heirs, assigns, and legal representatives. The rights of Employee hereunder are personal and may not be assigned or transferred except as may be agreed to in writing by the Company.
ARTICLE 10.
ARBITRATION

10.1) Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least 10 years. If the parties cannot agree on an arbitrator within 20 days, any party may request that the chief judge of the District Court for Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement, but without submission of the dispute to such Association. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator's fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys' fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

IN WITNESS WHEREOF, the parties have executed this Agreement and caused it to be dated as of the day and year first above written.

TECHNE CORPORATION

By /s/ Thomas E. Oland
Its President
"Company"

/s/ Marcel Veronneau
"Employee"
CERTIFICATION

I, Thomas E. Oland, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Techne Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

   a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

   a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

   b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 5, 2008

/s/ Thomas E. Oland
Chief Executive Officer
CERTIFICATION

I, Gregory J. Melsen, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Techne Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

   a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

   a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

   b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 5, 2008

/s/ Gregory J. Melsen
Gregory J. Melsen
Chief Financial Officer
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Techne Corporation (the "Company")
On Form 10-Q for the quarter ended December 31, 2007 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
Thomas E. Oland, Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or
15 (d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company.

/s/ Thomas E. Oland
-------------------------
Chief Executive Officer
February 5, 2008
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Techne Corporation (the "Company")
On Form 10-Q for the quarter ended December 31, 2007 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
Gregory J. Melsen, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or
15 (d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company.

/s/ Gregory J. Melsen
-------------------------
Chief Financial Officer
February 5, 2008